HC Advisors’s Cogent Biosciences COGT Stock Holding History

HC Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-31,395	Closed	-$353K	–	93
2020 Q4	$353K	Buy	+31,395	New	+$345K	0.24%	54

Other funds holding COGT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HC Advisors's COGT Position: Q1 2021 in Review

HC Advisors sold out of Cogent Biosciences (COGT) in Q1 2021, closing a stake of 31,395 shares — an estimated $353K sold.

HC Advisors first reported a position in COGT in Q4 2020 and held it in 1 quarter. The position peaked at $353K in Q4 2020. 69 funds tracked by Wall St. Rank hold COGT as of Q1 2021.

HC Advisors reported no remaining Cogent Biosciences position as of Q1 2021 after selling out during the quarter.
HC Advisors sold 31,395 Cogent Biosciences shares in Q1 2021, an estimated $353K.
HC Advisors first reported a position in Cogent Biosciences in Q4 2020 and held it in 1 quarter.
HC Advisors's Cogent Biosciences position peaked at $353K in Q4 2020.
69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2021.

Based on HC Advisors's 13F filing for Q1 2021, filed 7 May 2021.